Stay updated on BCD-021 vs Lucentis in Wet AMD Clinical Trial
Sign up to get notified when there's something new on the BCD-021 vs Lucentis in Wet AMD Clinical Trial page.

Latest updates to the BCD-021 vs Lucentis in Wet AMD Clinical Trial page
- Check5 days agoChange DetectedThe record describes the withdrawn GALATIR Phase 3 study comparing BCD-021 (bevacizumab) with Lucentis® (ranibizumab) for wet age-related macular degeneration. It includes the study design, eligibility criteria, outcomes, participating locations, and record dates.SummaryDifference52%

- Check12 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA sitewide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the ClinicalTrials.gov 403 error page. The footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating restricted access to the study record. The previous study content and related sections have been replaced by the error screen, obscuring the GALATIR trial details.SummaryDifference18%

- Check61 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0. This reflects a system-level update to the page's revision metadata rather than any substantive content changes.SummaryDifference0.1%

Stay in the know with updates to BCD-021 vs Lucentis in Wet AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-021 vs Lucentis in Wet AMD Clinical Trial page.